Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Public ClinicalTrials.gov record NCT04301011. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04301011
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Turnstone Biologics, Corp.
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- TBio-6517 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2020
- Primary completion
- Jan 22, 2023
- Completion
- Jan 22, 2023
- Last update posted
- Apr 22, 2025
2020 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Sylvester Comprehensive Cancer Center / UMHC | Miami | Florida | 33136 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66205 | — |
| Clinical Site 1007 | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| The Billings Clinic | Billings | Montana | 31031 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04301011, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04301011 live on ClinicalTrials.gov.